摘要
目的探讨甲巯咪唑联合美托洛尔对甲状腺功能亢进合并冠心病患者甲状腺相关激素和血浆N末端B型利钠肽原(NT-proBNP)的影响。方法选择甲状腺功能亢进合并冠心病的患者94例,按照随机数字表法分为对照组(n=47)和观察组(n=47),对照组患者使用丙基硫氧密啶片联合美托洛尔进行治疗,观察组患者使用甲巯咪唑联合美托洛尔进行治疗,对比治疗的效果。结果经过治疗后,两组患者的血清TSH、FT3、FT4浓度均降低,观察组的降低幅度大于对照组,差异有统计学意义(t=5.669、4.257、4.142,P<0.05)。经过治疗后,两组患者的心率、血浆NT-proBNP浓度、左心室射血分数、左心室舒张末期内径、左心室收缩末期内径均改善,观察组的改善幅度大于对照组,差异有统计学意义(P<0.05)。观察组的治疗效果优于对照组,差异有统计学意义(Z=1.872,P<0.05)。两组患者的各项不良反应数据差异无统计学意义(P>0.05)。结论使用甲巯咪唑联合美托洛尔治疗甲状腺功能亢进合并冠心病的患者,可以改善甲状腺相关激素以及心脏功能指标的恢复,安全性良好。
Objective To investigate the effect of methimazole combined with metoprolol on thyroid-related hormone and plasma N-terminal B-type natriuretic peptide(NT-proBNP)in patients with hyperthyroidism complicated with coronary heart disease.Methods Ninty-four patients with hyperthyroidism and coronary heart disease treated in our hospital from April 2016 to July 2018 were enrolled.According to the random number table method,the patients were randomly divided into the control group(n=47)and the observation group(n=47).Patients in the control group were treated with propylthioxidine tablets in combination with metoprolol.Patients in the observation group were treated with methimazole and metoprolol.The treatment effect was compared.Results After treatment,serum TSH,serum FT3,and serum FT4 concentrations were significantly reduced in the two groups,which was significantly more prominent in the observation group(P<0.05).After treatment,the heart rate,plasma NT-proBNP concentration,left ventricular ejection fraction,left ventricular end-diastolic diameter,and left ventricular end-systolic diameter were significantly improved in both groups;which were significantly more prominent in the observation group(P<0.05).The therapeutic effect of the observation group was significantly better than that of the control group(Z=1.872,P<0.05).There were no significant differences in adverse data between the two groups(P>0.05).Conclusion The use of methimazole combined with metoprolol in the treatment of patients with hyperthyroidism and coronary heart disease can improve the recovery of thyroid-related hormones and cardiac function indicators,with good safety.
作者
杨永红
任廷芳
张宇杰
易思叶
林明春
YANG Yong-hong;REN Ting-fang;ZHANG Yu-jie;YI Si-ye;LIN Ming-chun(Clinical Laboratory,Guizhou Orthopaedic Hospital,Guiyang 550007,Guizhou,China)
出处
《广东医学》
CAS
2020年第2期174-178,共5页
Guangdong Medical Journal
